

STENTYS Reports 38% Increase in Revenues in First Quarter 2016

PRINCETON, N.J. and PARIS – April 13, 2016 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces its revenues for the first quarter of 2016.

- Change in quarterly revenues*

€ thousands	Q1 2016	Q1 2015	% change
Revenues	1,512.0	1,094.0	+38.2%

* Unaudited

STENTYS recorded revenues of €1.5 million during the first quarter of 2016, up 38% over the same period in 2015. This growth was a result of the sustained demand for the Xposition S stent.

Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, comments: "2016 is starting off on the right track, as illustrated by our first-quarter sales. As a reminder, Q1 revenue growth last year was 28% over the prior year. Sales are expected to continue to increase, notably with the indications that were just CE Marked, such as treatment of lower-limb and left main coronary artery diseases."

- Upcoming financial press release

STENTYS expects to publish its revenues for the first half of 2016 on July 12, 2016

About STENTYS

STENTYS is developing and commercializing innovative solutions for the treatment of patients with complex artery disease. STENTYS' Self-Apposing® drug-eluting stents are designed to adapt to vessels with ambiguous or fluctuating diameters in order to prevent the malapposition problems associated with conventional stents. The APPOSITION clinical trials in the treatment of acute myocardial infarction showed a very low one year mortality rate and a faster arterial healing compared to conventional stents. The company's product portfolio also includes MiStent SES®, a coronary DES whose new drug delivery mechanism is designed to match vessel response, and is marketed through STENTYS' commercial network in Europe, the Middle East, Asia and Latin America.

More information is available at www.stentys.com.

Safe Harbor Statements

This press release contains forward-looking statements about the Company that are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which it will operate in the future which may not be accurate. Such forward-looking statements involve known and unknown risks which may cause the Company's actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with the development and commercialization of the Company's products, market acceptance of the Company's products, its ability to manage growth, the competitive environment in relation to its business area and markets, its ability to enforce and protect its patents and proprietary rights, uncertainties related to the U.S. FDA approval process, slower than expected rates of patient recruitment for clinical trials, the outcome of clinical trials, and other factors, including those described in the Section 4 "Risk Factors" of the Company's 2014 Registration Document (document de référence) filed with the French *Autorité des Marchés Financiers* (AMF) on July 29, 2015 under number D.15-0807 and as updated in section 4.1 of the Registration Document Update filed with the AMF on February 11, 2016 under number D.15-0807-A01.

STENTYS

Stanislas Piot
CFO
Tel.: +33 (0)1 44 53 99 42
stan.p@stentys.com

NewCap

Investor Relations / Strategic Communications
Dusan Oresansky / Pierre Laurent
Tel.: +33 (0)1 44 71 94 93
stentys@newcap.fr

STENTYS is listed on Comp. B of the NYSE Euronext Paris
ISIN: FR0010949404 – Ticker: STNT